Capturing the pharmaceutical value of biodiversity in a developing country

Environmental and Resource Economics

Volumn 8, Issue 2, 1996, Pages 157-181

  Barbier, Edward B ^a   Aylward, Bruce A ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b INTERNATIONAL INSTITUTE FOR ENVIRONMENT AND DEVELOPMENT   (United Kingdom)

Author keywords

biodiversity; biotic sample; conservation; developing country; pharmaceutical prospecting; protection; royalty; taxonomic information

Indexed keywords

BIODIVERSITY CONSERVATION; DEVELOPING COUNTRY; ENVIRONMENTAL ECONOMICS; GENETIC RESOURCES; PHARMACEUTICAL INDUSTRY; PHARMACEUTICAL PROSPECTING; ROYALTY RETURN; TAXONOMIC INFORMATION;

COSTA RICA;

DEVELOPING COUNTRIES; DRUG PRODUCTS PLANTS; ECOSYSTEMS; ENVIRONMENTAL PROTECTION; INDUSTRIAL ECONOMICS; MATHEMATICAL MODELS;

BIODIVERSITY PROTECTION; BIOTIC SAMPLE; ROYALTIES; TAXONOMY;

DRUG PRODUCTS;

EID: 0029659689     PISSN: 09246460     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00357362     Document Type: Article

References (26)

1. Aylward, B. A. (1992), 'Appropriating the value of wildlife and wildlands', in T. M. Swanson and E. B. Barbier, eds., Economics for the Wilds, London: Earthscan Publications.
2. Aylward, B. A. (1993), 'The economic value of pharmaceutical prospecting and its role in biodiversity conservation', LEEC Paper DP 93-05, London: London Environmental Economics Centre.
3. Aylward, B. A., J. Echeverría, L. Fendt, and E. B. Barbier (1993), 'The economic value of species information and its role in biodiversity conservation: Costa Rica's National Biodiversity Institute', LEEC Paper 93-06. London: London Environmental Economics Centre.
4. Balandrin, M., Klocke, E. Wurtele, and W. Bollinger (1995), 'Natural plant chemicals: sources of industrial and medicinal material', Science 288, 1154.
5. Ballance, R., J. Pogány, and H. Forstner (1992), The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy, Edward Elgar, Aldershot, UK.
6. Barbier, E. B., J. C. Burgess, and C. Folke (1994), Paradise Lost? The Ecological Economics of Biodiversity, Earthscan Publications, London.
7. Cragg, G. M., M. R. Boyd, J. H. Cardellina III, M. R. Grever, S. A. Shepartz, and K. M. Snader (1993), 'The role of plants in the drug discovery program of the United States Cancer Institute', in D. R. Buxton et al., eds., International Crop Science 1. Wisconsin: Crop Science Society of America.
8. Daly, Douglas (1992), B. A. Krukoff Curator of Amazonian Botany, the New York Botanical Garden. Personal communication.
9. DiMasi, J. A., R. W. Hansen, H. G. Grabowske, and L. Lasagna (1991), 'Cost of innovation in the pharmaceutical industry', Journal of Health Economics 10, 107-142.
10. Douros, J. and M. Stiffness (1980), 'The National Cancer Institute's Natural Products Antineoplastic Development Program', in S. K. Carter and Y. Sakurai, eds., Recent Results in Cancer Research, Vol. 70, pp. 21-44, Berlin: Springer-Verlag.
11. Farnsworth, N. and R. Morris (1976), 'Higher plants - the sleeping giant of drug development', American Journal of Pharmacy 148(2), 46-52.
12. Findeisen, C. and S. Laird (1991), Natural Products Research and the Potential Role of the Pharmaceutical Industry in Tropical Forest Conservation, Report prepared by The Periwinkle Project of the Rainforest Alliance, New York.
13. Garrity, George (1992), Senior Research Fellow, Microbial Resources, Merck & Co. Personal communication.
14. Grabowski, H. and Vernon, J. (1990), 'A new look at the returns and risks to pharmaceutical R&D', Management Science 36 (July), 804-821.
15. Janzen, D. (1990), A North-South Perspective on Science in the Management, Use, and Economic Development of Biodiversity. Paper prepared for the International Conference on Conservation of Genetic Resources for Sustainable Development, Roros, Norway, 10-14 September.
16. Laird, S. (1992) The Commercialization of Biological Samples: Contracts for the Prospecting of Biodiversity, Draft paper, Periwinkle Project, Rainforest Alliance, New York.
17. Lewin, A., J. van Door, M. Flint, and R. Solóranzo (1992), Biodiversity Conservation in Costa Rica. An evaluation of the Guanacaste and INBio projects prepared for SIDA and MIRENEM. Swedish International Development Authority, Stockholm.
18. Mallincrodt, E. and S. Laird (1992), Update of Pharmaceutical Industry Involvement in Natural Products Research, Paper prepared by the Periwinkle Project of the Rainforest Alliance, New York.
19. Sedjo, R. A. (1992) 'Property rights, genetic resources, and biotechnological change', The Journal of Law & Economics 35(1), 199-213.
20. Simpson, R. D. (1992) Transactional Arrangements and the Commercialization of Tropical Biodiversity, ENR Discussion Paper 92-11, Resources for the Future, Washington DC.
21. Simpson, R. D., R. A. Sedjo, and J. W. Reid (1995), 'Valuing biodiversity for use in pharmaceutical research', forthcoming in Journal of Political Economy.
22. Suffness, M., D. J. Newman, and K. Snader (1989), 'Discovery and development of antineoplastic agents from natural sources', in Bioorganic Marine Chemistry, Volume 3, pp. 131-168. Berlin: Springer-Verlag.
23. Townes, H. K. (1992), 'Charging fees for taxonomic services', Association of Systematics Collections Newsletter 20(4), 129-131.
24. Tyler, V. (1979), 'Plight of plant-drug research in the United States today', Economic Botany 33(4), 377-383.
25. U.S. News and World Report (1992), 'The troubling ghosts of scourges past', October 26, pp. 70-71.
26. World Resource Institute (WRI) (1992) Global Biodiversity Strategy, WRI, Washington DC.